Annex 7

Principal Investigator's declaration for clinical research on remuneration and reporting obligations in Medsol

Undersigned, as the principal investigator of the study wthe prtocol No
, hereby declare that I accept and apply the principle of Semmelweis
University for the allocation of study fees, according to which the principal investigator's share of the
study fee shall be a maximum of 25% of the amount remaining after deduction of the co-payment and
the university contribution for the conduct of the study, while 75% of the remaining amount shall be
paid to the other participants of the study.
I further agree that it is the responsibility of the principal investigator to ensure that, under Government
Decree 43/1999 (III.3.), the status of benefits for medical research is recorded in the MedSol IT system
as "B" (other funded), funder: 6 (drug research) in reimbursement category "F", and that complication
benefits for medical research are reported to the National Health Insurance Fund Manager in
reimbursement category "G".
The completed and signed Investigator's Declaration must be sent electronically in PDF format only to klinikaikutatas@semmelweis-univ.hu .
Date:
Signature of Principal Investigator

Version: V1/20220712